Compare REKR & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | TARA |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 165.5M |
| IPO Year | N/A | N/A |
| Metric | REKR | TARA |
|---|---|---|
| Price | $1.55 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,028,000.00 | N/A |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $22.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.89 | N/A |
| 52 Week Low | $0.62 | $2.77 |
| 52 Week High | $3.42 | $7.82 |
| Indicator | REKR | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 39.19 |
| Support Level | $1.37 | $5.18 |
| Resistance Level | $1.65 | $5.80 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 54.41 | 3.90 |
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).